ARQT Stock Analysis
AR
Uncovered
Arcutis Biotherapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. The company is headquartered in Westlake Village, California and currently employs 268 full-time employees. The company went IPO on 2020-01-31. The company is focused on developing and commercializing treatments for dermatological diseases with unmet medical needs. The company harnesses its dermatology development platform to build therapies against biologically validated targets. Its dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions. The company’s lead program, topical roflumilast, has the potential to advance the care for plaque psoriasis of the body and scalp, atopic dermatitis and seborrheic dermatitis. The company is developing roflumilast cream for the treatment of plaque psoriasis, including psoriasis in intertriginous regions, such as the groin, axillae and inframammary areas, as well as atopic dermatitis. The company is also developing ARQ-252 is topical cream formulation of a potent and selective small molecule inhibitor of JAK1 and is developing it for chronic hand eczema and vitiligo.